Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07844213 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone"

Name: Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone" — clinical trial record (NCT07844213)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusCompleted

PhaseNot applicable

SponsorChina National Center for Cardiovascular Diseases

Started2022-08-25

View on ClinicalTrials.gov ↗

China National Center for Cardiovascular Diseases

127 trials monitored

See 4 trials at risk

Heart Disease

2,117 trials monitored

See 101 trials at risk

Hypertension

1,786 trials monitored

See 77 trials at risk

The purpose of this study is to observe the efficacy of early application of triple targeted drug therapy, including trilostane, in patients with congenital heart disease who are in the "gray zone" of preoperative evaluation, have surgical repair indications after evaluation, and have undergone defect repair.

Trial Details

NCT Number	NCT07844213
Lead Sponsor	China National Center for Cardiovascular Diseases
Conditions	Congenital Heart Disease, Pulmonary Hypertension
Enrollment	30 participants
Start Date	2022-08-25
Primary Completion	2025-07-30 (estimated)
Study Completion	2025-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-28